Syros Pharmaceuticals (NASDAQ:SYRS) was upgraded by BidaskClub from a “hold” rating to a “buy” rating in a research note issued to investors on Thursday.
A number of other equities research analysts have also issued reports on the stock. HC Wainwright reaffirmed a “hold” rating and set a $10.00 price objective on shares of Syros Pharmaceuticals in a report on Wednesday, March 14th. Wedbush reaffirmed an “outperform” rating and set a $13.00 price objective (up from $11.00) on shares of Syros Pharmaceuticals in a report on Tuesday, March 13th. Zacks Investment Research lowered shares of Syros Pharmaceuticals from a “buy” rating to a “hold” rating and set a $12.00 price objective for the company. in a report on Saturday, January 20th. Oppenheimer set a $28.00 price objective on shares of Syros Pharmaceuticals and gave the company a “buy” rating in a report on Monday, January 8th. Finally, Cowen reaffirmed a “buy” rating on shares of Syros Pharmaceuticals in a report on Monday, December 11th. One analyst has rated the stock with a sell rating, three have given a hold rating and seven have given a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $21.13.
Shares of Syros Pharmaceuticals stock opened at $12.75 on Thursday. Syros Pharmaceuticals has a fifty-two week low of $6.30 and a fifty-two week high of $24.38. The stock has a market cap of $412.40, a P/E ratio of -6.01 and a beta of -2.26.
In other news, Director Srinivas Akkaraju bought 209,424 shares of the stock in a transaction dated Wednesday, January 31st. The stock was purchased at an average cost of $9.55 per share, for a total transaction of $1,999,999.20. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. 33.60% of the stock is currently owned by corporate insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Two Sigma Advisers LP bought a new position in shares of Syros Pharmaceuticals during the 4th quarter valued at approximately $105,000. Adalta Capital Management LLC bought a new position in shares of Syros Pharmaceuticals during the 4th quarter valued at approximately $111,000. Russell Investments Group Ltd. bought a new position in shares of Syros Pharmaceuticals during the 3rd quarter valued at approximately $133,000. Cubist Systematic Strategies LLC bought a new position in shares of Syros Pharmaceuticals during the 3rd quarter valued at approximately $149,000. Finally, The Manufacturers Life Insurance Company boosted its position in shares of Syros Pharmaceuticals by 11,253.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 10,559 shares of the company’s stock valued at $170,000 after acquiring an additional 10,466 shares during the last quarter. Hedge funds and other institutional investors own 49.33% of the company’s stock.
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.